Pharmaceutical Composition Containing Expanded Adult Stem Cells and Methods of Using Same for Treatment

Abstract

A method for the expansion of adult stem cells from blood, particularly but not only peripheral blood, involves removing adult stem cells from blood of a mammal, immediately expanding the stem cells via in-vitro treatment with MCSF (Macrophage Colony Stimulating Factor) at a concentration of about 8-15 nM, and purifying the expanded stem cells. Compositions and methods of using the expanded adult stem cells are also described.

1 . A pharmaceutical composition comprising an active principle comprising expanded adult stem cells and at least one of a pharmacologically acceptable adjuvant and an excipient, wherein the expanded adult stem cells are obtained using a method comprising:
 a) obtaining a sample of blood of an adult mammal;   b) immediately after the sample of blood has been taken from the mammal, treating the sample of blood in vitro with MCSF (macrophage colony stimulating factor) at a concentration of about 8-15 nM MCSF to obtain expanded stem cells in the sample of blood; and   c) purifying the expanded stem cells.   
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein the expanded adult stem cells are contained at a concentration of about 90-250×10 3  cells/ml in the pharmaceutical composition, and the pharmaceutical composition is formulated for intravenous injection. 
     
     
         3 . The pharmaceutical composition according to  claim 1 , wherein the expanded adult stem cells are contained at a concentration of about 4-40×10 6  cells/ml in the pharmaceutical composition, and the pharmaceutical composition is formulated for local or topical application. 
     
     
         4 . The pharmaceutical composition according to  claim 1 , further comprising at least one antibiotic as an active principle at a concentration of about 5-15 nM. 
     
     
         5 . The pharmaceutical composition according to  claim 4 , where the antibiotic is gentamicin. 
     
     
         6 . The pharmaceutical composition according to  claim 4 , where the antibiotic is amikacin. 
     
     
         7 . A method of treating a lesion in a mammal, comprising administering to the mammal a medication comprising the pharmaceutical composition according to  claim 1 , wherein the lesion is selected from the group consisting of a cutaneous lesion, a lesion to a tendon, a lesion to a ligament, a lesion to a bone, and a lesion to mucous membranes. 
     
     
         8 . A method of treating a fracture in a mammal, comprising administering to the mammal a medication comprising the pharmaceutical composition according to  claim 1 . 
     
     
         9 . A method of treating a neurological or neurodegenerative pathology in a mammal, comprising administering to the mammal a medication comprising the pharmaceutical composition according to  claim 1 , wherein the neurological or neurodegenerative pathology is selected from the group consisting of Cushing's disease, head shaking, Wobbler's syndrome, breathing difficulties, and paresis of the limbs. 
     
     
         10 . A method of treating an acute or chronic inflammatory pathology in a mammal, comprising administering to the mammal a medication comprising the pharmaceutical composition according to  claim 1 , wherein the acute or chronic inflammatory pathology is selected from the group consisting of laminitis, periostitis, gastritis, arthrosis, and an inflammation caused by at least one of viral, bacterial, parasite, and mycotic agents. 
     
     
         11 . A method of treating a syndrome of dilatation-torsion of the stomach in a mammal, comprising administering to the mammal a medication comprising the pharmaceutical composition according to  claim 1 . 
     
     
         12 . A method of treating infertility in a mare, precocity in a colt, or for improving competitive activity or performance in a mammal, the method comprising administering to the mare, the colt or the mammal, respectively, a medication comprising the pharmaceutical composition according to  claim 1 . 
     
     
         13 . The method according to  claim 7 , wherein the expanded adult stem cells are contained in the pharmaceutical composition at a concentration of about 150×10 3  cells/ml, and wherein the medication is administered once a week intravenously. 
     
     
         14 . The method according to  claim 7 , wherein the mammals is selected from the group consisting of a human, a horse, a cat, and a dog. 
     
     
         15 . A method of preparing the pharmaceutical composition according to  claim 1 , comprising mixing the expanded adult stem cells with the at least one of the pharmacologically acceptable adjuvant and the excipient.